Patients should be informed that HepaGam B™ (hepatitis b immune globulin (human)) (Hepatitis B Immune Globulin Intravenous [Human]) is prepared from human plasma. Products made from human plasma may contain infectious agents such as viruses that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses during manufacturing. Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products.
Individuals known to have severe, potentially life-threatening reaction to human globulin should not receive HepaGam B (hepatitis b immune globulin (human)) or any other immune globulin products. Individuals who are deficient in IgA may have the potential for developing IgA antibodies and have severe potentially life threatening allergic reactions. In case of allergic or anaphylactic reaction, the infusion should be stopped immediately. In case of shock, the current medical standards for treatment of shock should be observed.
The maltose contained in HepaGam B (hepatitis b immune globulin (human)) can interfere with some types of blood glucose monitoring systems. Only testing systems that are glucose-specific should be used in patients receiving HepaGam B (hepatitis b immune globulin (human)) . This inference can result in falsely elevated glucose readings that can lead to untreated hypoglycemia or to inappropriate insulin administration, resulting in life-threatening hypoglycemia.
Last reviewed on RxList: 2/20/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional HepaGam B Information
Report Problems to the Food and Drug Administration
Find out what women really need.